Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial. The randomized, investigator-initiated trial evaluates a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. DUBSTENT DIABETES investigates the safety and efficacy of combining drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) implantation compared to single-device strategies […]
teleflex
Teleflex recalls certain Arrow epidural catheterization kits in Europe
Teleflex (NYSE:TFX) subsidiary Arrow issued an urgent field safety notice in Europe to warn of failures with the loss of resistance (LOR) syringes including in epidural catheterization kits. The company received complaints regarding the syringes in the kits that revealed dural puncture with some also requiring a blood patch. An inadvertent dural puncture may lead […]
Teleflex launches connected asthma management device
Teleflex (NYSE:TFX ) today launched its AsthmaMD Peak Flow Meter, a device designed to help patients with asthma track their lung performance. The Wayne, Penn.-based company’s device integrates with the AsthmaMD smartphone app, which digitally logs peak flow meter readings, symptoms and medication use. The app also helps patients share the collected data with their physicians […]
